Current Hypertension Reports

, 11:456 | Cite as

Direct renin inhibition: An update



Aliskiren, the first orally effective direct renin inhibitor, is an effective antihypertensive agent with distinctive properties including placebo-like tolerability, pharmacologic effects that persist after drug discontinuation, and a unique mechanism of action. When combined with agents that inhibit the reninangiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or β-blockers, additional blood pressure reduction reflects more complete RAAS blockade. Concern that marked elevation in plasma renin concentration following aliskiren administration might lead to RAAS-induced paradoxical blood pressure increases appears unfounded, based upon analyses of patients participating in clinical trials. Studies in animals and humans indicate that aliskiren accumulates in renal tissue, blocks the intrarenal RAAS, and interferes with deleterious cellular effects of angiotensin II by mechanisms that may include enzymatic blockade of renin and prorenin at the site of the (pro)renin receptor. In patients with diabetic nephropathy, adding aliskiren to losartan resulted in an additional 20% reduction in urinary protein excretion. In patients with heart failure, aliskiren reduced brain natriuretic peptide levels when added to other RAAS inhibitors, suggesting an additional hemodynamic effect. The ASPIRE HIGHER clinical trials program is assessing whether the promising pharmacologic properties of aliskiren translate into long-term clinical benefits.

References and Recommended Reading

  1. 1.
    Dahlöf B, Anderson DR, Arora V, et al.: Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension [abstract]. J Clin Hypertens 2007, 9(Suppl A):A157.Google Scholar
  2. 2.
    Oparil S, Yarows SA, Patel S, et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370:221–229.CrossRefPubMedGoogle Scholar
  3. 3.
    Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients [abstract]. Am J Hypertens 2004, 17:S108.CrossRefGoogle Scholar
  4. 4.
    Stanton A, Jensen C, Nussberger J, O’Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42:1137–1143.CrossRefPubMedGoogle Scholar
  5. 5.
    Schmieder RE, Philipp T, Guerediaga J, et al.: Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009, 119:417–425.CrossRefPubMedGoogle Scholar
  6. 6.
    European Medicines Agency: European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines [press release]. London: February 19, 2009. Available at Accessed September 17, 2009.
  7. 7.
    Pool J, Gradman A, Kolloch R, et al.: Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 2006, 119(suppl 27):790.Google Scholar
  8. 8.
    Palatini P, Jung W, Shlyakhto E, et al.: Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2009 May 21 (Epub ahead of print).Google Scholar
  9. 9.
    Oh BH, Mitchell J, Herron JR, et al.: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007, 49:1157–1163.CrossRefPubMedGoogle Scholar
  10. 10.
    Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217–226.CrossRefPubMedGoogle Scholar
  11. 11.
    Uresin Y, Taylor A, Kilo C, et al.: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007, 8:190–198.CrossRefPubMedGoogle Scholar
  12. 12.
    Dietz R, Dechend R, Yu CM, et al.: Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008, 9:163–175.CrossRefPubMedGoogle Scholar
  13. 13.
    Sealey JE, Laragh JH: Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007, 20:587–597.CrossRefPubMedGoogle Scholar
  14. 14.
    Campbell DJ: Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008, 51:15–18.CrossRefPubMedGoogle Scholar
  15. 15.
    Danser AH, Charney A, Feldman DL, et al.: The renin rise with aliskiren: it’s simply stoichiometry. Hypertension 2008, 51:e27–e28.CrossRefPubMedGoogle Scholar
  16. 16.
    Stanton A, Gradman AH, Schmieder R, et al.: Aliskiren does not cause paradoxical rises in blood pressure [abstract P-56]. J Clin Hypertens 2009, 11(s1):A39.Google Scholar
  17. 17.
    Kelly DJ, Zhang Y, Moe G, et al.: Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007, 50:2398–2404.CrossRefPubMedGoogle Scholar
  18. 18.
    Feldman DL, Jin L, Xuan H, et al.: Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52:130–136.CrossRefPubMedGoogle Scholar
  19. 19.
    Fisher ND, Jan Danser AH, Nussberger J, et al.: Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008, 117:3199–3205.CrossRefPubMedGoogle Scholar
  20. 20.
    Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417–1427.PubMedGoogle Scholar
  21. 21.
    de Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309–2320.CrossRefPubMedGoogle Scholar
  22. 22.
    Parving HH, Persson F, Lewis JB, et al.; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.CrossRefPubMedGoogle Scholar
  23. 23.
    Solomon SD, Appelbaum E, Manning WJ, et al.; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530–537.CrossRefPubMedGoogle Scholar
  24. 24.
    Westermann D, Riad A, Lettau O, et al.: Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008, 52:1068–1075.CrossRefPubMedGoogle Scholar
  25. 25.
    Latini R, Masson S, Anand I, et al., for the Val-HeFT Investigators: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292–299.CrossRefPubMedGoogle Scholar
  26. 26.
    McMurray JJV, Pitt B, Latini R, et al., for the Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17–24.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Cardiovascular DiseasesThe Western Pennsylvania Hospital and Temple University School of MedicinePittsburghUSA

Personalised recommendations